Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/36138
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorComi, G.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorWiendl, H.-
dc.contributor.authorWuerfel, J.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorDirks, P.-
dc.contributor.authorKuenzel, T.-
dc.contributor.authorKadner, K.-
dc.contributor.authorVermersch, P.-
dc.date.accessioned2021-12-11T19:57:22Z-
dc.date.available2021-12-11T19:57:22Z-
dc.date.issued2021-
dc.date.submitted2021-12-08T09:43:48Z-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 27 (2_SUPPL) , p. 543 -544-
dc.identifier.urihttp://hdl.handle.net/1942/36138-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleEfficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results-
dc.typeJournal Contribution-
dc.identifier.epage544-
dc.identifier.issue2_SUPPL-
dc.identifier.spage543-
dc.identifier.volume27-
local.format.pages2-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isiWOS:000706771302003-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Van Wijmeersch, B.] Hasselt Univ, Univ MS Ctr, Pelt, Hasselt, Belgium.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
local.description.affiliation[Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain.-
local.description.affiliation[Wiendl, H.] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany.-
local.description.affiliation[Wuerfel, J.] Univ Basel, Med Image Anal Ctr MIAC AG, Basel, Switzerland.-
local.description.affiliation[Wuerfel, J.] Univ Basel, Dept Biomed Engn, Basel, Switzerland.-
local.description.affiliation[Buffels, R.; Dirks, P.; Kuenzel, T.; Kadner, K.] F Hoffmann La Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Vermersch, P.] Univ Lille, Inserm U 1172 LilNCog, CHU Lille, FHU Precise, Lille, France.-
local.uhasselt.internationalyes-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorComi, G.-
item.contributorOreja-Guevara, C.-
item.contributorWiendl, H.-
item.contributorWuerfel, J.-
item.contributorBuffels, R.-
item.contributorDirks, P.-
item.contributorKuenzel, T.-
item.contributorKadner, K.-
item.contributorVermersch, P.-
item.fulltextNo Fulltext-
item.fullcitationVAN WIJMEERSCH, Bart; Comi, G.; Oreja-Guevara, C.; Wiendl, H.; Wuerfel, J.; Buffels, R.; Dirks, P.; Kuenzel, T.; Kadner, K. & Vermersch, P. (2021) Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results. In: MULTIPLE SCLEROSIS JOURNAL, 27 (2_SUPPL) , p. 543 -544.-
item.accessRightsClosed Access-
crisitem.journal.eissn2055-2173-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on May 2, 2024

Page view(s)

50
checked on Aug 1, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.